On this page
- Supraventricular arrhythmias (fibrillation, flutter, paroxysmal tachycardia)
- Heart failure
Forms and strengths
- 250 micrograms (0.25 mg) tablet
- Adult: 125 to 250 micrograms (0.125 to 0.25 mg) once daily
- Reduce the dose by half in elderly patients and in patients with renal impairment.
- According to clinical response
Contra-indications, adverse effects, precautions
- Do not administer to patients with bradycardia, ill defined arrhythmia, coronary artery disease.
- It is essential to monitor pulse in the initial stage of treatment.
- Narrow margin between therapeutic and toxic dose.
- May cause in the event of overdose: gastrointestinal disturbances (nausea, vomiting, diarrhoea), blurred vision, headache, confusion, conduction and rhythm disorders. If so, reduce dose or stop treatment.
- Do not combine with calcium, particularly by IV route (serious arrhythmias).
- Monitor combination with:
- amiodarone, macrolides, itraconazole, quinine, chloroquine (increased digoxin concentration);
- potassium-depleting drugs: diuretics, corticoids, amphotericin B (increased risk of digoxin toxicity).
- Monitor if possible serum potassium level in patients taking potassium-depleting drugs and serum creatinine level in patients with renal impairment.
- Do not administer simultaneously with antacids such as aluminium hydroxide, etc., administer 2 hours apart.
- Pregnancy: no contra-indication
- Breast-feeding: no contra-indication
- Below 25 °C